$SRDX (SurModics, Inc.)

$SRDX {{ '2016-01-11T16:02:47+0000' | timeago}} • Announcement

Medical device maker $SRDX said it has acquired NorMedix, a privately owned design and development company focused on ultra thin-walled, minimally invasive catheter technologies based in Plymouth, Minn. This acquisition strengthens $SRDX's vascular device expertise and research and development (R&D) capabilities.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$HRC {{ '2017-07-19T14:11:03+0000' | timeago}} • Announcement

$HRC declared a dividend of $0.18 per share for 4Q17 payable on September 29, 2017, to shareholders of record as of September 15, 2017. The indicated annual dividend rate is $0.72 per share.

$HAE {{ '2017-06-23T10:51:04+0000' | timeago}} • Announcement

$HAE announced the formation of a Scientific Advisory Council as part of its broader innovation agenda, advancing its commitment to science and clinical excellence. The SAC will also, as appropriate, provide opinion on strategic issues impacting product and clinical matters.

$REGN {{ '2017-06-22T14:02:42+0000' | timeago}} • Announcement

$REGN provided details of the royalty it receives on any sales of canakinumab (ACZ885). $REGN received a royalty on worldwide net sales of canakinumab; the royalty rate starts at 4% and reaches 15% when canakinumab annual sales exceed $1.5Bil.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$GE {{ '2017-06-14T12:04:29+0000' | timeago}} • Announcement

$GE's GE Additive and $SYK have entered a partnership agreement to support $SYK's growth in additive manufacturing. The agreement covers new additive machines, materials and services for $SYK's global supply chain operations.

$REGN {{ '2017-06-12T10:58:03+0000' | timeago}} • Announcement

$REGN and $SNY announced positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes. In the studies, Praluent, when administered on top of maximally tolerated doses of statins, significantly reduced low-density lipoprotein cholesterol, the primary endpoint of the study.

$REGN {{ '2017-06-05T12:01:45+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive preliminary results with investigational REGN2810 in patients with advanced cutaneous squamous cell carcinoma (CSCC). CSCC is the second most common type of skin cancer in the U.S.

$HRC {{ '2017-05-26T13:49:04+0000' | timeago}} • Announcement

$HRC's BoD declared 3Q17 dividend of $0.18 per share. The dividend is payable on June 30, 2017, to shareholders of record on June 16, 2017. The indicated annual dividend rate is $0.72 per share.

$REGN {{ '2017-05-23T12:31:01+0000' | timeago}} • Announcement

$REGN said the U.S. Food and Drug Administration (FDA) approval of Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease modifying antirheumatic drugs, such as methotrexate (MTX).

$TFX {{ '2017-05-15T11:14:58+0000' | timeago}} • Announcement

$TFX commenced the Phase I clinical study of RePlas, a lyophilized fresh frozen plasma product being developed in collaboration with the U.S. Army Medical Materiel Development Activity (USAMMDA). The early administration of plasma has an important role in reducing trauma mortality from uncontrolled bleeding (hemorrhage).

$SYK {{ '2017-05-08T16:05:41+0000' | timeago}} • Announcement

$SYK said its subsidiary Howmedica Osteonics will move forward with the 2016 Settlement Program that provides for compensation to additional eligible U.S. patients who had surgery to replace their Rejuvenate Modular-Neck hip stem and/or ABG II Modular-Neck hip stem, known as a revision surgery, prior to Dec. 19, 2016.

$SYK {{ '2017-05-08T16:04:06+0000' | timeago}} • Announcement

$SYK said its subsidiary Howmedica Osteonics has informed the courts in the New Jersey Multicounty and Federal Multidistrict litigations that 95% of additional registered eligible patients have enrolled in the Settlement Program under the Master Settlement Agreement announced in December 2016.

$REGN {{ '2017-05-08T12:57:32+0000' | timeago}} • Announcement

$REGN and SillaJen, Inc. announced a new clinical and supply agreement for a Phase 1b dose-escalation study in renal cell carcinoma. Under the terms of the agreement, the trial will be solely conducted and funded by SillaJen based upon a mutually developed study design and $REGN will provide REGN2810.

$REGN {{ '2017-05-08T12:56:18+0000' | timeago}} • Announcement

$REGN and SillaJen, Inc. announced a new clinical and supply agreement for a Phase 1b dose-escalation study in renal cell carcinoma. The open-label trial is expected to begin later this year, and is designed to evaulate the safety and efficacy of REGN2810 in combination with Pexa-Vec compared to treatment with REGN2810 as monotherapy.

$TFX {{ '2017-05-08T12:46:37+0000' | timeago}} • Announcement

$TFX's BoD declared a quarterly cash dividend of $0.34 per share of common stock. The dividend is payable on June 15, 2017 to shareholders of record at the close of business on May 15, 2017.

$REGN {{ '2017-05-08T12:38:36+0000' | timeago}} • Announcement

$REGN and $INO announced a clinical study agreement for a phase 1b/2a immuno-oncology trial for glioblastoma combination therapy. Glioblastoma is the most common and aggressive type of brain cancer. The open-label trial is expected to begin later this year.

$HAE {{ '2017-05-08T10:25:43+0000' | timeago}} • Announcement

$HAE expects FY18 revenue to approximate FY17 revenue and adjusted EPS of $1.55-1.65. The company predicts FY18 operating income of about 10-11% of revenue and adjusted operating income of 13-14% of revenue. Adjusted free cash flow is expected to be about $35-55MM.

$HAE {{ '2017-05-08T10:25:25+0000' | timeago}} • Announcement

$HAE reported a wider loss in 4Q17 due to higher impairment of assets and a decline in revenue. Net loss widened to $51.14MM or $0.98 per share from $8.74MM or $0.17 per share last year. Revenue fell 5.9% to $228.07MM. Adjusted EPS increased to $0.39 from $0.37.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, May 3 2017 - 9:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, April 28 2017 - 12:30pm
RMD (ResMed Inc.)
Thursday, April 27 2017 - 8:30pm
SRDX (SurModics, Inc.)
Thursday, April 27 2017 - 12:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
GMED (Globus Medical, Inc.)
Monday, February 27 2017 - 10:30pm
TFX (Teleflex Incorporated)
Thursday, February 23 2017 - 1:00pm
CRY (CryoLife Inc.)
Thursday, February 16 2017 - 1:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, February 9 2017 - 10:00pm
PTN (Palatin Technologies Inc.)
Thursday, February 9 2017 - 4:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, February 9 2017 - 1:30pm
HAE (Haemonetics Corporation)
Monday, February 6 2017 - 1:00pm

AlphaGraphics you may like